Gaboxadol

Gaboxadol
Clinical data
Other namesTHIP; 4,5,6,7-tetrahydroisoxazolo(5,4-c)pyridin-3-ol; LU-2-030; OV101; OV-101
Routes of
administration		Oral
Drug classGABAA receptor agonist; Sedative; Hypnotic; Central depressant; Hallucinogen
ATC code
  • None
Identifiers
  • 4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridin-3(2H)-one
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.059.039
Chemical and physical data
FormulaC6H8N2O2
Molar mass140.142 g·mol−1
3D model (JSmol)
  • O=C1/C2=C(\ON1)CNCC2
  • InChI=1S/C6H8N2O2/c9-6-4-1-2-7-3-5(4)10-8-6/h7H,1-3H2,(H,8,9) Y
  • Key:ZXRVKCBLGJOCEE-UHFFFAOYSA-N Y
  (verify)

Gaboxadol, also known as 4,5,6,7-tetrahydroisoxazolo(5,4-c)pyridin-3-ol (THIP), as well as by its former developmental code names LU-2-030 and OV101, is a conformationally constrained derivative of the alkaloid and Amanita muscaria constituent muscimol. It acts as a direct GABAA receptor agonist. At lower doses, the drug has sedative and hypnotic effects, and at higher doses, it has hallucinogenic effects. Gaboxadol was studied for potential medical use as a pharmaceutical drug for a variety of indications, most notably treatment of insomnia, but was ultimately never marketed.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.